Physician profile
David Corallo
NPI 1225126212
$9,797.50
in general payments reported to CMS, 2019-2025
40 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,304 · 2020: $835 · 2021: $1,341 · 2022: $1,540 · 2023: $1,781 · 2024: $1,538 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,596 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,596.47 |
| Education | $180.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,099.21 | 2019-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $1,163.09 | 2019-2025 | Jardiance, Mounjaro, Lyumjev |
| Amgen INC. | $862.08 | 2019-2025 | Otezla, Otezla, Repatha |
| Corcept Therapeutics | $680.41 | 2019-2023 | Korlym |
| Genzyme Corporation | $641.86 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $527.08 | 2019-2025 | |
| Janssen Biotech, INC. | $518.62 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $452.72 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $433.13 | 2019-2024 | Dupixent |
| Ucb, INC. | $308.57 | 2020-2025 | Bimzelx |
| Incyte Corporation | $254.04 | 2022-2024 | Opzelura |
| Merck Sharp & Dohme LLC | $172.29 | 2019-2022 | |
| Novo Nordisk INC | $169.35 | 2020-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.97 | 2020-2024 | Spevigo |
| Recordati_rare_diseases_inc. | $139.85 | 2023 | Isturisa, Signifor Lar |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Corallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.